Fast Five Quiz: Confronting Obesity

Romesh Khardori, MD, PhD; Elif A. Oral, MD

Disclosures

January 31, 2022

In order to promote long-term weight maintenance, guidelines from the Endocrine Society recommend the use of an approved weight loss medication over not using pharmacologic therapy in patients with a BMI of ≥ 30 or a BMI of ≥ 27 and at least one associated comorbid medical condition (eg, hypertension, type 2 diabetes, dyslipidemia). In patients with cardiovascular disease who seek pharmacologic treatment for weight loss, orlistat is recommended. In addition, the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (2.4-mg/week subcutaneous dose) was approved by the US Food and Drug Administration in June 2021 for patients with an initial BMI of ≥ 30 and for those with a BMI of ≥ 27 in the presence of at least one weight-related comorbid condition. The approval was based on four phase-3 clinical trials involving approximately 4500 patients with overweight or obesity that showed a 15%-18% weight loss over 68 weeks.

The guidelines also recommend against the use of the sympathomimetic agents phentermine and diethylpropion in patients who have obesity with a history of cardiovascular disease or uncontrolled hypertension.

For patients who present with obesity the guidelines recommend using antidiabetic medications that have additional actions to promote weight loss (eg, GLP-1 analogs, sodium-glucose cotransporter 2 [SGLT] inhibitors) in addition to metformin.

Learn more about the pharmacologic treatment of obesity.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....